Lupin launches long-acting Risperidone in US
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
AGA affects up to 80 per cent of men across their lifetime and remains one of the most common and most psychologically challenging forms of hair loss
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
This is the first drug to receive a recommendation for this preventative indication in the European Union
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
Subscribe To Our Newsletter & Stay Updated